文献速递临床微生物分子诊断

VITEK REVEAL快速药敏试验与纸片扩散法在革兰阴性菌血流感染中的比较

Comparison of VITEK REVEAL fast antimicrobial susceptibility testing to antibiotic disk diffusion for gram-negative bloodstream infections.
PubMed 文献 · J Clin Microbiol · 2025-11-14

本研究纳入150例革兰阴性菌阳性血培养,比较VITEK REVEAL快速药敏试验与纸片扩散法的性能及工作流程。结果显示VITEK REVEAL联合MALDI-TOF MS可将药敏报告时间从37.2-54.7小时缩短至14.0小时,总体分类一致率为97.0%,极重大误差2.9%,重大误差0.3%。

要点

  • VITEK REVEAL联合MALDI-TOF MS将药敏报告时间缩短至少23小时。
  • 总体分类一致率97.0%,极重大误差2.9%,重大误差0.3%。
  • 产ESBL表型菌株分类一致率93.2%,极重大误差2.0%,重大误差0.7%。

核心结论

  • VITEK REVEAL联合MALDI-TOF MS的工作流程较标准纸片扩散法将药敏报告时间缩短至少23小时,总体分类一致率为97.0%。

研究设计与样本

  • 研究纳入150例单种革兰阴性菌阳性血培养,其中大肠埃希菌47.3%(71/150)、肺炎克雷伯菌17.3%(26/150)、铜绿假单胞菌15.3%(23/150),其余为其他肠杆菌目及1株不动杆菌属。

主要发现

  • 标准工作流程(纸片扩散法联合多重耐药菌分级检测)的药敏总报告时间为37.2-54.7小时,而MALDI-TOF MS联合VITEK REVEAL流程为14.0小时。
  • 声称的菌-抗生素组合分类一致率为97.0%,极重大误差2.9%(8/279),重大误差0.3%(5/1957),差异结果经肉汤微量稀释法裁定。
  • 产ESBL表型菌株(n=29)分类一致率为93.2%,极重大误差2.0%,重大误差0.7%。

临床怎么用

  • VITEK REVEAL需依赖独立方法(如质谱或核酸扩增)先完成菌种鉴定,再直接从阳性血培养进行药敏检测。
  • 该联合流程可加速革兰阴性菌血流感染的靶向治疗并限制不必要的广谱抗生素使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The VITEK REVEAL antimicrobial susceptibility testing (AST) system is a fast in vitro diagnostic device that determines the antimicrobial susceptibility profile of gram-negative organisms from positive blood culture after independent organism identification. The objectives of this study were to (i) compare the performance of VITEK REVEAL to disk diffusion (DD) and (ii) evaluate implementation of VITEK REVEAL into a laboratory workflow that employs matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) as the primary method for organism identification. A total of 150 monomicrobial, GN-positive blood cultures were enrolled, of which 47.3% (71/150) contained Escherichia coli, 17.3% (26/150) Klebsiella pneumoniae, and 15.3% (23/150) Pseudomonas aeruginosa, with the remaining comprising other Enterobacterales and one Acinetobacter spp. The time to result (TTR) from blood culture positivity to AST results was compared for DD with tiered testing for multidrug-resistant organisms and VITEK REVEAL. Overall, the standard-of-care workflow had a combined TTR for AST of 37.2-54.7 h, while the workflow of MALDI-TOF MS + VITEK REVEAL had a TTR of 14.0 h due to the time necessary to identify the organism using MALDI-TOF MS. The categorical agreement (CA) for claimed organism-antibiotic combinations was 97.0%, with a very major discrepancy (VMD) of 2.9% (8/279) and a major discrepancy (MD) of 0.3% (5/1957), following adjudication of discrepant results with broth microdilution. The CA for organisms with an extended-spectrum beta-lactamase phenotype (n = 29) was 93.2%, with VMD of 2.0%, and MD of 0.7%. In conclusion, the VITEK REVEAL reduced the TTR for AST by at least 23 h compared to standard-of-care DD, with a CA of 97%.IMPORTANCEBloodstream infections caused by gram-negative bacteria require effective and timely treatment. Laboratory testing informs the choice of antibiotics, but traditional methods can require multiple days for results. The VITEK REVEAL system determines antibiotic susceptibility directly from a positive blood culture within 8 h, though it requires an independent method for organism identification, such as mass spectrometry or nucleic acid amplification testing. In this study, we examined VITEK REVEAL as part of a workflow incorporating mass spectrometry for organism identification. This combined approach provided susceptibility results approximately 1 day earlier than standard disk diffusion while maintaining high accuracy for most organism-antibiotic combinations, including those active against multidrug-resistant organisms. Incorporating VITEK REVEAL into routine laboratory workflows has the potential to accelerate targeted therapy and limit unnecessary broad-spectrum use in patients with gram-negative bloodstream infections.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Bui TI, Brown AP, Muenks CE, et al. Comparison of VITEK REVEAL fast antimicrobial susceptibility testing to antibiotic disk diffusion for gram-negative bloodstream infections. J Clin Microbiol. 2025. PMID: 41235945. doi:10.1128/jcm.00927-25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。